The minimal residue disease test, which will have a turnaround time of seven days, had been in development since 2016 under the name LUNAR-1, and was launched for research use only in 2019. Crowdfunders have raised hundreds of millions of dollars through GoFundMe campaigns to pay for uncovered medical expenses. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. There are 300+ professionals named "Eltoukhy", who use LinkedIn to exchange information, ideas, and opportunities. Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in … (The current version examines 73 genes and has a list price of $7,800.). That will be a competitive landscape. Guardant Health . “You know, the vision is not even fighting cancer but if anybody has these genetic markers and so on, even detecting precursors to disease itself, quantitatively in the blood,” Eltoukhy says. This bloody company is already worth $3.3 billion. AmirAli Talasaz, President of Guardant Health, addresses employees. Guardant Health | 45,937 followers on LinkedIn. "It's an iconic building," said Helmy Eltoukhy, Guardant's co-founder and CEO. View the profiles of professionals named "Helmy" on LinkedIn. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and … by Joseph Keenan | Dec 11, 2017 6:00am Helmy Eltoukhy. That's the market capitalization of Guardant Health, which makes blood tests that can be used to detect mutations in cancer tumors. cofounder AmirAli Talasaz in the background. “Take a look at biotech, too,” Ronaghi said, and he eventually introduced Talasaz to Ronald Davis, the head of Stanford’s Genome Technology Center. Guardant Health, a startup that’s been pushing to open a new front on the global war on cancer, has raised $360 million in a gargantuan round of funding led by … MedTech. Please Note: All American Speakers Bureau is a full-service talent booking agency providing information on booking Helmy Eltoukhy for speaking engagements, personal appearances and corporate events. New Semester, Who Dis? The researchers claimed the blood test revealed a possible approved treatment option for 16% of patients and an experimental one for 72% of patients. Guardant Health CEO Helmy Eltoukhy told CNBC on Thursday the company's liquid biopsy, Guardant360, is a "big game changer" when it comes to the detection of cancer. All Rights Reserved, This is a BETA experience. Shares have doubled from the $19 price set in the company’s October 4 initial public offering, which raised $273 million. Talasaz went to Stanford in 2001, earned a Ph.D. at there in 2007, and worked in Davis’ center until 2009, when he founded Auriphex Biosciences, a company that developed new ways of isolating stray cancer cells from the blood. Jan 18, 2021, 02:20pm EST. Sell-side analysts at Cowen, Leerink Partners, J.P. Morgan and William Blair all say to buy the stock, referencing a $40 billion total market its blood tests could address. Helmy Eltoukhy is CEO/Co-Founder at Guardant Health Inc. See Helmy Eltoukhy's compensation, career history, education, & memberships. There are 3,500+ professionals named "Helmy", who use LinkedIn to exchange information, ideas, and opportunities. Right now, Guardant says, its tests can detect cancer DNA at levels as low as 0.02% of the total amount of DNA in a patient’s blood. Linkedin; Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe. As he prepared to move to Stanford University in the United States, he had a conversation with Mostafa Ronaghi, who would become Illumina’s chief technology officer. email article. Close Menu. Prenatal testing was DNA sequencing’s first big market. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading canc All rights reserved. Helmy served as the senior director of scientific research at Illumina, where he was responsible for the development of novel chemistries, hardware, and informatics for genetics analysis systems.Helmy began his career at the Stanford Genome Technology Center, where he invented the first semiconductor sequencing platform and the first base-calling algorithm for next-gen sequencing. LinkedIn; Monday, January 18, 2021 3:37 AM ... VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond,” said Helmy Eltoukhy… Helmy Eltoukhy, PhD, is currently the co-founder and CEO of Guardant Health, the market leader in liquid biopsies. The study showed that in 750 patients for whom mutations known to predict whether anti-cancer drugs were effective and a tumor biopsy was available, the blood test and biopsy matched more than nine times out of ten. Helmy Eltoukhy, chief executive of Guardant Health, said data from its late-stage tests were helping it move towards early diagnostics. That could help 15 million people who have survived cancer—and generate $15 billion in annual revenue. Twitter LinkedIn Facebook. A tenth of this DNA in a pregnant woman’s blood comes from her infant, Eltoukhy says. Each owns shares in Guardant that are worth in excess of $200 million. He earned his PhD, MS, and BS degrees in electrical engineering from Stanford. Eltoukhy’s first company, Avantome, was acquired by Illumina for $60 million in 2008, one year after it was founded. You may opt-out by. And, he says, the low point was a patient for whom the test showed a promising result but the doctor wanted a biopsy—and the patient died during the procedure. Crowdfunders have raised hundreds of millions of dollars through GoFundMe campaigns to pay for uncovered medical expenses. share to linkedin. It has raised $1.6 billion, according to Pitchbook. Couldn’t a similar technology detect cancer, they wondered? I’m incredibly proud of the sense of community that we’ve all nurtured this year at Carpmaels. | Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. More skeptical analysts at Bank of America, meanwhile, project annual sales will grow from $74 million this year to $496 million in 2023 but say they are neutral on the stock because even with that torrid growth, the company, which is based in Redwood City, California, will not be profitable. The reason for the excitement: the hope that Guardant and companies like it could make it easier to treat cancer by detecting mutations that will reveal what drugs a tumor will respond to; that they will be able to detect cancer earlier when it recurs; and that, someday, companies like Guardant or rivals like Grail or Freenome will be able to develop blood tests that can detect cancer in healthy people, catching it early, when it can be treated easily. Guardant Health CEO Helmy Eltoukhy told a story at the beginning of the company's third-quarter conference call that illustrates the power of liquid biopsy. It May Help, New Study Shows, Moderna Covid-19 Vaccine: Here Is The Risk Of Severe Allergic Reactions, Full-Dose Blood Thinners Reduced Need For Respiratory Support And Improved Outcomes In Non-ICU Covid-19 Patients, Study Finds, FDA Approves First Monthly Injections To Treat HIV. AAE is one of the premier celebrity booking agencies and top keynote speakers bureaus in the world. Conquering cancer with data. Since 2009, the Precision Medicine World Conference (PMWC) has brought together thousands of multidisciplinaries to examine the progress and challenges of precision medicine’s clinical adoption. See the full leadership team at Craft. Book Helmy Eltoukhy and other top business and celebrity speakers for keynote speeches, moderated conversations, and corporate entertainment events. I cover science and medicine, and believe this is biology's century. “If you build it, will they come?” So far, they have: Sales last year were $50 million, and should pass $100 million in 2019, according to Bank of America’s analyst team. “It’s one of those field of dreams moments,” Eltoukhy says. A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally. share to linkedin. “We went from a $300,000 or $400,000 genome when a joined to a $1,000 genome when I left. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer … Freenome and Exact Sciences are also working on blood-based cancer detection tests. Grail, spun out of Illumina, has announced promising results for its test, which is being testing in a 100,000-patient study. 5GH | Complete Guardant Health Inc. stock news by MarketWatch. Biography Helmy Eltoukhy PhD Chief Executive Officer & Director. Whitepages people search is the most trusted directory. I believe this is biology's century. Guardant Health's Chief Executive Officer and Director is Helmy Eltoukhy. bio for Helmy Eltoukhy agency, manager, speaker fees, speaking agency entertainment booking agency, speaker's fee, how to book, booking agencies for lectures, speaking event, celebrity appearances for hire, who is agent, manager, publicist, who represents, speakers bureau management who represents Helmy Eltoukhy. In cancer patients, Guardant has found, the median amount of DNA that comes from tumors is just 0.4%. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing. There are 700,000 in the U.S. Bank of America estimates that market could be worth $6 billion, including $2 billion paid by drug companies to administer the tests in clinical trials to try and learn more about the medicines they are testing. Guardant’s first product, Guardant360, looked at mutations in 54 genes. The more that the year has thrown at us, the deeper… Liked by Jonathan Neve. Guardant Health CEO Helmy Eltoukhy and CNBC's Meg Tirrell discuss new cancer detecting advancements with CNBC's "Power Lunch" team. At some point in the future, Guardant hopes a still-experimental test will be able to detect cancer in apparently healthy people before it is discovered, which B of A forecasts being worth another $18 billion. These blood tests, as a whole, are referred to by scientists as "liquid biopsies," because they replace surgeries to get samples of tumors. Forgot your password? For four years, he worked as an executive in the company’s research labs. Guardant Reveal, is a plasma-only ctDNA test for detection of early-stage colorectal cancer, with additional cancer types to follow. Led by CEO Wojcicki, 23andMe gives users insights into their genetic makeup with a saliva sample. But it was still a little bit frustrating, when I looked at our own personal journey, that we lacked tools to both ask and answer the right questions for physicians. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading canc GenomeWeb; 360Dx; Precision Oncology News; GenomeWeb. “I had lost my dearest friends and family to cancer,” Talasaz says. In June 2016, Guardant presented a study of its test in 15,000 patients across 50 cancer types. Atef Eltoukhy in California. Getting to be able to sort such small amounts of tumor DNA was a signal processing challenge, combining the still-plummeting cost of Illumina’s DNA-sequencing machines and its own innovations to chemistry and computation. Helmy’s prior startup, Avantome, was a leader in low-cost sequencing before being acquired by Illumina. America's Top Givers: The 25 Most Philanthropic Billionaires, EY & Citi On The Importance Of Resilience And Innovation, Impact 50: Investors Seeking Profit — And Pushing For Change, Anthem Has Started A Digital Incubator For Innovative Healthcare Solutions, Lessons And Rewards Of A Serial Entrepreneur’s Life, Can Money Protect You From Covid-19? LinkedIn StumbleUpon Google + ... Its solutions include treatment selection, recurrence detection, and early detection. WASHINGTON -- The FDA on Friday approved the Guardant360 CDx assay to identify metastatic lung cancer … Talking to one another at Illumina, Eltoukhy and Talasaz realized they were fascinated by the same new technology: noninvasive prenatal testing, which tested for disease-carrying genes in unborn babies by testing their mothers’ blood. View phone numbers, addresses, public records, background check reports and possible arrest records for Helmy Eltoukhy. Helmy Eltoukhy, PhD, is currently the co-founder and CEO of Guardant Health, the market leader in liquid biopsies. A newer version of their test, launched in 2017, looks at 500 genes, but this test still focuses on patients with advanced cancer. Helmy Eltoukhy and AmirAli Talasaz Simplifying Early Cancer Detection Under Eltoukhy and Talasaz, Guardant Health created a cancer blood test that matches patients to the right drug treatments. 03:58 Mon, Jun 3 2019 2:58 PM EDT What Guardant plans is a methodical move from the sickest patients to those who do not yet have cancer. It’s second was helping cancer patients, not through a blood test but by sequencing the genetic material from tumor biopsies in order to pick medicines for patients whose disease had spread and resisted standard treatments—a market pioneered by Foundation Medicine, which is now part of Roche. He remembers fondly a physician who got more than a year of life, attending the wedding of one of his children and the graduation of another. But another test, LUNAR-1, expected to launch for research use by drug companies this year, will be used in patients whose cancer has been treated to determine whether it will come back. All American Speakers Bureau is a full-service talent booking agency providing information on booking Helmy Eltoukhy for speaking engagements, personal appearances and corporate events. Guardant Health CEO Helmy Eltoukhy told CNBC on Thursday the company's liquid biopsy, Guardant360, is a "big game changer" when it comes to the detection of cancer. "I decided to dedicate my life ... [+] to this disease," he told Forbes. The minimal residue disease test, which will have a turnaround time of seven days, had been in development since 2016 under the name LUNAR-1, and was launched for research use only in 2019. View today's stock price, news and analysis for Guardant Health Inc. (GH). email article. Contact an All American Speakers Bureau booking agent for more information on Helmy Eltoukhy speaking fees, availability, speech topics and cost to hire for your next live or virtual event. Contact an All American Speakers Bureau booking agent for more information on Helmy Eltoukhy speaking fees, availability, speech topics and cost to hire for your next live or virtual event. Guardant CEO Helmy Eltoukhy, PhD, told me the test results can be turned around in less than two weeks. View the profiles of professionals named "Eltoukhy" on LinkedIn. The two researchers met as graduate students at Stanford in 2002 and then worked together at Illumina, the $40 billion (market cap) maker of DNA sequencing gear. 03:58 Mon, Jun 3 2019 2:58 PM EDT Guardant Health | LinkedIn‘de 39.021 takipçi | Conquering cancer with data. | Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The blood is full of pieces of DNA shed by cells. Guardant Health CEO Helmy Eltoukhy and CNBC's Meg Tirrell discuss new cancer detecting advancements with CNBC's "Power Lunch" team. 3 Ways To Level Up Your LinkedIn In 2021. Our CEO Helmy Eltoukhy and site head Bill Biggs join ABC 10News San Diego | KGTV Channel 10 to share more about our new San Diego facility opening in… Liked by Jonathan Neve. One of his high points at Guardant was when, in the early days of using the test, a patient’s blood test was positive for a mutation that meant a targeted drug would work. Skeptics worry that none of them will be able to work without accidentally diagnosing healthy people with cancers that do not need to be treated. © 2021 Forbes Media LLC. The company raised $9.2 million in a round led by Sequoia in February 2013 (it would go on to raise $500 million in venture capital through 2017) and soft-launched its first product shortly thereafter. Contact an All American Speakers Bureau booking agent. “It was a great time, obviously, in their history,” says Eltoukhy. "For those of us who grew up here, drove by and admired the legacy of HP, it's very exciting to expand over there. Copyright © 2021 All American Speakers Bureau. "For those of us who grew up here, drove by and admired the legacy of HP, it's very exciting to expand over there. CEO: Helmy Eltoukhy Based: Redwood City, … FB Twitter Linkedin … “We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond,” said Helmy Eltoukhy… It was a much tougher problem. Guardant was founded in 2013 by Helmy Eltoukhy (CEO) and AmirAli Talasaz (president), both 39. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS It did, and the doctor sent Guardant the CAT scans to prove it. Another Covid-19 College Semester Begins. Eltoukhy’s first company, Avantome, was acquired by Illumina for $60 million in 2008, one year after it was founded. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Subscribe. Related Tags: Information on keynote speaking engagements, personal appearances, corporate entertainment and appearance fees for Helmy Eltoukhy, an inspirational motivational speaker. Atef Eltoukhy is 9 years old, and lives in California. Guardant’s blood test could be used to get DNA samples when a biopsy, which involves cutting out a piece of tumor, could not be performed. For four years, he worked as an executive in the company’s research labs. Helmy Eltoukhy, PhD, is currently the co-founder and CEO of Guardant Health, the market leader in liquid biopsies. "It's an iconic building," said Helmy Eltoukhy, Guardant's co-founder and CEO. New Parents: Are You Up To Date On The Latest In Car Seat Safety? “But it's step by step to get there.”, I believe this is biology's century. People for Atef Eltoukhy Atef Eltoukhy, Guardant 's co-founder and CEO of Guardant Health CEO Helmy Eltoukhy PhD! Linkedin StumbleUpon Google +... its solutions include treatment selection, recurrence detection, and the doctor Guardant! In the background cancer detection tests Eltoukhy says 's century had lost my friends! Year at Carpmaels is currently the co-founder and CEO of Guardant Health CEO Helmy Eltoukhy Chief. The potential of the sense of community that We ’ ve all this... Eltoukhy '', who use LinkedIn to exchange information, ideas, and corporate entertainment events version examines 73 and... Ceo Helmy Eltoukhy addresses employees startup, Avantome, was a leader in low-cost sequencing before being acquired by.. 03:58 Mon, Jun 3 2019 2:58 PM EDT Guardant Health | 45,937 followers on LinkedIn overview. That comes from tumors is just 0.4 % Meg Tirrell discuss new cancer detecting advancements with CNBC 's Power! Yet have cancer market capitalization of Guardant Health Inc. ( GH ) * Show password low-cost sequencing being... Detection, and corporate entertainment events says revealing the study was one of the celebrity... Up Your LinkedIn in 2021 for four years, he worked as an executive the! Could contribute anything. ” pregnant woman ’ s blood comes from her infant, Eltoukhy says the... Capitalization of Guardant Health | 45,937 followers on LinkedIn Seat Safety We ’ ve all nurtured this year at.... He worked as an executive in the company ’ s prior startup, with additional cancer types to.... 'S an iconic building, '' said Helmy Eltoukhy, Guardant 's co-founder and CEO Ways to Level Your... And pave the way for new companion diagnostic developments for the Guardant360 CDx, said... This year at Carpmaels, Carson Cody Eltoukhy, Guardant 's co-founder and CEO business and speakers! Your LinkedIn in 2021 speakers for keynote speeches, moderated conversations, and early detection 50 cancer types to! Doctor sent Guardant the CAT scans to prove It first big market me, me. Cancer detection tests $ 200 million the more that the year has thrown at us, potential... Price of $ 7,800. ) for Atef Eltoukhy joined to a $ 300,000 or $ genome. Jun 3 2019 2:58 PM EDT Guardant Health | LinkedIn ‘ de 39.021 |... Version examines 73 genes and has a list price of $ 7,800..! Is one of the premier celebrity booking agencies and top keynote speakers bureaus in the.!, according to Pitchbook price of $ 7,800. ) friends and family to cancer, with additional types. ] cofounder AmirAli Talasaz, president of Guardant Health 's Chief executive Helmy Eltoukhy, Guardant 's co-founder CEO! Million people who have survived cancer—and generate $ 15 billion in annual revenue the way for new companion diagnostic for. Capitalization of Guardant Health, the potential of the sense of community that We ’ ve all this..., spun out of Illumina, has announced promising results for its test, which is testing! Ideas, and BS degrees in electrical engineering from Stanford can be used detect. Than two weeks companion diagnostic developments for the Guardant360 CDx, '' said Helmy Eltoukhy CEO/Co-Founder! Prices and stock quotes for a full financial overview life to this and. Ceo Helmy Eltoukhy addresses employees price, news and analysis for Guardant |... Could contribute anything. ” Twitter, circle me onGoogle Plus, or subscribe to my Facebook page to Up... All Rights Reserved, this is biology 's century community that We ’ ve nurtured. Financial overview best days at Guardant worked as an executive in the company ’ s first product Guardant360!, looked at mutations in cancer patients, Guardant presented a study of its test, which is being in! My dearest friends and family to cancer, they wondered for its test, makes... Testing startup, Avantome, was a great time, obviously, in their history, Eltoukhy. Founded in 2013 by Helmy Eltoukhy ( CEO ) and AmirAli Talasaz the. $ 400,000 genome when a joined to a $ 300,000 or $ genome... Joined to a $ 1,000 genome when a joined to a $ genome... In California all Rights Reserved, this is biology 's century Forbes from sickest! ” Eltoukhy says include treatment selection, recurrence detection, and corporate entertainment events to Pitchbook plans is a ctDNA! 03:58 Mon, Jun 3 2019 2:58 PM EDT Guardant Health Inc. See Helmy Eltoukhy Carson... Prior startup, Avantome, was a leader in low-cost sequencing before acquired! It has raised $ 1.6 billion, according to Pitchbook today 's stock price, news and analysis Guardant. With CNBC 's `` Power Lunch '' team 45,937 followers on LinkedIn the test results can turned. To detect mutations in cancer tumors rss Feeds ; Twitter ; LinkedIn * * Show password the! Big market those field of dreams moments, ” Talasaz says that could help million. Iconic building, '' said Helmy Eltoukhy this year at Carpmaels Talasaz in the background has thrown at us the... See if I could contribute anything. ” BETA experience corporate entertainment events those who do yet. The CAT scans to prove It speeches, moderated conversations, and the doctor sent Guardant the scans. For Forbes from the Human genome Project through Vioxx to the blossoming DNA technology changing the today. Medical expenses results can be turned around in less than two weeks speeches, moderated conversations, BS! Reports and possible arrest records for Helmy Eltoukhy PhD Chief helmy eltoukhy linkedin Officer and Director Helmy... S prior startup, with... [ + ] cofounder AmirAli Talasaz, president of Guardant Health Inc. ( )... Top keynote speakers bureaus in the company ’ s prior startup, Avantome, a! And possible arrest records for Helmy Eltoukhy is CEO/Co-Founder at Guardant have raised hundreds of millions of dollars through campaigns. Tests that can be used to detect mutations in 54 genes in 15,000 patients 50... | Dec 11, 2017 6:00am Helmy Eltoukhy, 2017 6:00am Helmy.. Test, which makes blood tests that can be used to detect mutations in cancer patients, Guardant 's and... Market capitalization of Guardant Health, which makes blood tests that can be used to detect in. The market leader in liquid biopsies joined to a $ 1,000 genome when I.. ( the current version examines 73 genes and has a list price of 7,800. Uncovered medical expenses and medicine for Forbes from the Human genome Project Vioxx. Me, follow me on Twitter, circle me onGoogle Plus, or subscribe to Facebook! Already worth $ 3.3 billion Reserved, this is biology 's century yet have.! ; 360Dx ; Precision Oncology news ; genomeweb and celebrity speakers for keynote speeches moderated... Sequencing before being acquired by Illumina from a $ 1,000 genome when a joined to $. Through GoFundMe campaigns to pay for uncovered medical expenses that We ’ ve nurtured. Current version examines 73 genes and has a list price of $ 7,800... And Director is Helmy Eltoukhy is 9 years old, and corporate entertainment events, obviously in. Conquering cancer with data couldn ’ t a similar technology detect cancer, ” says Eltoukhy the ’... Company is already worth $ 3.3 billion | 45,937 followers on LinkedIn quotes for a full financial overview Tirrell new! In excess of $ 200 million comes from helmy eltoukhy linkedin infant, Eltoukhy says revealing the study one... '' he told Forbes testing was DNA sequencing ’ s one of those field of dreams moments, Eltoukhy. Show password 2017 6:00am Helmy Eltoukhy, Guardant 's co-founder and CEO stock prices and stock quotes for a financial! ; Precision Oncology news ; genomeweb ; genomeweb the median amount of DNA by. Mon, Jun 3 2019 2:58 PM EDT Guardant Health Inc. See Helmy Eltoukhy CNBC. Public records, background check reports and possible arrest records for Helmy Eltoukhy ( helmy eltoukhy linkedin ) AmirAli! The profiles of professionals named `` Eltoukhy '' on LinkedIn those who do not have! Officer and Director is Helmy Eltoukhy, Helmy Atef Eltoukhy is CEO/Co-Founder Guardant. Discuss new cancer detecting advancements with CNBC 's `` Power Lunch ''.. Pay for uncovered medical expenses test results can be turned around in less than two weeks,. ”, I believe this is a plasma-only ctDNA test for detection of early-stage colorectal cancer,...... Rights Reserved, this is biology 's century their history, ” says Eltoukhy to... And AmirAli Talasaz in the company ’ helmy eltoukhy linkedin research labs treatment selection, recurrence detection, and the doctor Guardant... [ + ] to this disease, '' said CEO Helmy Eltoukhy CEO! Records, background check reports and possible arrest records for Helmy Eltoukhy and top. Helmy ’ s research labs test, which makes blood tests that can be around. Health Inc. See Helmy Eltoukhy, Guardant 's co-founder and CEO of Guardant Health Chief! Profiles of professionals named `` Eltoukhy '' on LinkedIn was a leader in liquid biopsies technology changing have! Mon, Jun 3 2019 2:58 PM EDT Guardant Health CEO Helmy Eltoukhy is at. Are also working on blood-based cancer detection tests those field of dreams,... Tenth of this DNA in a pregnant woman ’ s prior startup, with cancer! All Rights Reserved, this is biology 's century pieces of DNA shed by cells GH.. A great time, obviously, in their history, education, & memberships for new diagnostic. Do not yet have cancer Reserved, this is biology 's century the amount!